CSL Limited
(ASX:CSL) has announced David Lamont will replace Gordon Naylor as Chief Financial Officer.
Mr Naylor is moving on to head up the integrated bioCSL and Novartis flu vaccines business.
Mr Lamont has 30 years experience in company finance including CFO roles at Oz Minerals, Paperlinx and Incitec Pivot.
He will take up his new position on January 2, 2016.
CSL reported a net profit of $1.8 billion for the 2015 financial year.
